GSK-217744/095 (DTPa-HBV-IPV-095)

Study to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs' DTPa-HBV-IPV-Hib vaccine or GSK Biologicals' DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086
Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine
217744/095 (DTPa-HBV-IPV-095)
Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus
Phase 4
This is a booster to primary study 217744/086. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015